Risk factor
Very high price volatility
Profitability factor
Undervalued vs peers
In Guru Portfolios
Manager | Fund | Portfolio Weight (%) | Change |
|---|---|---|---|
| Kenneth Griffin | CITADEL ADVISORS LLC | 0.0% | -0.00% |
About
So-Young International Inc. manages a digital platform specializing in medical aesthetics and elective healthcare services, serving customers in the People's Republic of China and globally. This online ecosystem enables users to explore content, share personal experiences regarding medical aesthetic procedures, and book in-person treatments with various medical aesthetic service providers. The platform also offers resources for researching treatment trends, features ratings and reviews of treatment experiences, and publishes blogs under headings like "Beauty Diaries." Beyond cosmetic enhancements, So-Young facilitates reservations for a broader spectrum of healthcare needs, including dermatology, dentistry (with orthodontics), ophthalmology, comprehensive physical examinations, gynecology, human papillomavirus vaccinations, and postnatal support. The company also supplies Software-as-a-Service (SaaS) solutions and provides guidance and training programs to medical service providers. Its offerings extend to internet information and technology advisory, management consulting, and internet culture services. Furthermore, So-Young is involved in the sale of medical equipment, equipment manufacturing, sales, and agency services, as well as microfinance. As of December 31, 2021, its platform had established connections with approximately 8,400 medical aesthetic service providers and an additional 5,000 providers offering other consumption-focused healthcare services. Established in 2013, So-Young International Inc. maintains its corporate headquarters in Beijing, China.
Company Valuation
From both historical and forecast perspectives, the stock is underpriced compared to similar stocks.
Target Price
The average target price of SY is 8.20 and suggests 209% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas